Glenmark Pharmaceuticals (GLENMARK.BO) Earnings Analysis

Glenmark Pharmaceuticals (GLENMARK.BO) next reports earnings on 2026-07-31, consensus EPS 17.3 INR. Last quarter (2026-06-01) it missed with EPS 10.68 INR vs 18.2 INR est (-41.3%). It has beaten estimates in 1/7 recent quarters (14%). Trailing P/E 45.61.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does GLENMARK.BO next report earnings?

Next earnings date2026-07-31
Consensus EPS estimate17.3 INR
Revenue estimate39.17B

GLENMARK.BO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-06-0110.68 INR18.2 INR-41.3%Miss
2026-02-1214.28 INR18.7 INR-23.6%Miss
2025-11-1421.62 INRn/an/an/a
2025-08-131.66 INR12.9 INR-87.1%Miss
2025-05-238.75 INR12.1 INR-27.7%Miss
2025-02-1312.3 INR14.05 INR-12.5%Miss
2024-11-1412.55 INR14.7 INR-14.6%Miss
2024-08-1412.06 INR11.7 INR+3.1%Beat

Beat rate: 1/7 (14%) over reported quarters with consensus data.

GLENMARK.BO valuation and analyst view

Trailing P/E45.61
Trailing EPS48.254 INR
Price / book5.91
Dividend yield0.11%
Market cap620.39B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Glenmark Pharmaceuticals (GLENMARK.BO)'s next earnings date?

Glenmark Pharmaceuticals is next scheduled to report on 2026-07-31, with a consensus EPS estimate of 17.3 INR and revenue estimate of 39.17B.

Did GLENMARK.BO beat earnings last quarter?

In its 2026-06-01 report, GLENMARK.BO posted EPS of 10.68 INR versus a 18.2 INR estimate — a miss of 41.3%.

What is GLENMARK.BO's earnings track record?

Over the last 7 reported quarters with consensus data, GLENMARK.BO beat estimates 1 times (14%).

What is GLENMARK.BO's current P/E ratio and EPS?

GLENMARK.BO trades at a trailing P/E of 45.61 on trailing EPS of 48.25443000747636 INR.

What do analysts rate GLENMARK.BO?

GLENMARK.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.